Please login to the form below

Not currently logged in
Email:
Password:

UCB to sell Biogen Idec’s MS drugs in Asia

Includes Tysabri and Tecfidera
UCB

UCB will sell Biogen Idec's portfolio of multiple sclerosis (MS) and haemophilia treatments in several Asian countries as part of a new agreement between the companies.

The deal allows UCB to commercialise the medicines in South Korea, Hong Kong, Thailand, Singapore, Malaysia and Taiwan, while both partners will develop and commercial products in China.

Drugs included as part of the deal include the huge-selling Tysabri (natalizumab), which Biogen Idec gained full rights to last year after buying out partners Elan.

Tecfidera, which is Biogen Idec's entry into the new market for oral MS drugs, is also included in the deal and is well on its way to blockbuster status after being approved in the US at the beginning of 2013.

Outside MS, Biogen Idec's two haemophilia treatments – Eloctate and Alprolix - can also be commercialised by UCB in the specified Asian markets.

Biogen Idec's senior VP, emerging markets, Carlos Dourado said: “Our goal is to bring our innovative therapies to patients around the world as quickly and efficiently as possible.

"By leveraging UCB's extensive resources, expertise and infrastructure in Asia, we believe we can grow our footprint in critical Asian markets, get our therapies to patients more quickly and create a foundation for further commercial success in this region."

US-based Biogen Idec's previosu experience in the Asian market includes a biosimialrs joint venture with Korea's Samsung Biologics known as Samsung Bioepis.

Article by
Thomas Meek

31st January 2014

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics